This is old news, but Bayhill just decided to do this press release I guess...
Scientists Demonstrate Investigational MS Drug Down Regulates the Underlying Cause Believed Responsible for Multiple Sclerosis
BUSINESS WIRE - Dec. 19, 2005 - Scientists at Bayhill Therapeutics report promising findings for an investigational multiple sclerosis (MS) drug, BHT-3009, which represents a novel DNA plasmid-based approach for the treatment of the life-threatening disease.
In a number of patients with myelin basic protein ...
Read more : BHT-3009
| Views :
2364 | Replies :